Zeeuws Investment Fund
  • ABOUT US
    • ZIF
    • FUND MANAGER
  • CRITERIA
  • INVESTMENTS
    • TOXYS
    • DOVIDEQ MEDICAL
    • INNO4LIFE
    • MAGNETIC
    • MIMETAS
    • EAGLET EYE
    • SOTERIA MEDICAL
    • ILLUXTRON
  • NEWS
  • CAREERS
  • CONTACT
  • DUTCH

ZEEUWS INVESTMENT FUND INVESTS IN EAGLET EYE

1/5/2014

 
Eaglet Eye Zeeuws Investment Fund
.The Zeeuws Investment Fund invests in Eaglet Eye; a company that develops high-tech instruments for eye care professionals. The investment of the ZIF will mainly be used for the international launch of the ESP.

The ESP is a revolutionary precision instrument for the measurement of the eye, and of essential importance for the safe and comfortable fit of contact lenses, special contact lenses in particular. The ESP is the first device that is able to measure a diameter of 20mm of the eye surface. The technology was originally developed at the University of Maastricht and has seen continued development by parties in the Netherlands in cooperation with international experts in the optometry field.

Eaglet Eye CEO, Arnoud Snepvangers: “With the Zeeuws Investment Fund, we feel we have chosen the right investor to not only support us with their capital, but also with their knowledge and expertise. This allows our company to grow internationally and to realize the ambition to improve the quality of vision around the world, both for the patient and the ophthalmologist.”

Johan Sebregts, director of the Zeeuws Investment Fund: “Eaglet Eye fits very well into the ZIF portfolio. Eaglet Eye brings new and inspiring technology on the market and has the potential to become a global player in the field of precision instruments for eye care. We foresee a bright future for Eaglet Eye.”

More information about Eaglet Eye.

ZEEUWS INVESTMENT FUND INVESTS IN SOTERIA MEDICAL BV

1/1/2014

 
Soteria Medical BV Zeeuws Investment Fund
Together with the Innovation and Investment Fund Gelderland, the Zeeland Investment Fund invests in Soteria Medical BV. Soteria has developed a robotic arm that is used for prostate biopsies in an MRI environment. Soteria Medical completed the clinical trials in 2013 and will bring the robot arm on market in 2014. 

Prostate cancer is the most common form of cancer among men. As many as 1 out of 7 men will face prostate cancer. Increasingly, MRI is used to better analyze the development of aggressive tumors in the prostate and for taking a biopsy. 
One of the world’s leading centers in the field of detection and treatment of prostate cancer is the St. Radboud University Medical Center in Nijmegen. Patients from all over the Netherlands and around the world visit the St. Radboud because they apply the latest techniques. St. Radboud has developed a number of these techniques. 

One of these newly developed techniques is a robot that is able to automatically move the biopsy needle to a suspicious spot on the prostate, while the patient lies in the MRI. This procedure is performed faster and more accurately than other biopsy methods, resulting in an improved diagnosis and a more patient-friendly and cost-efficient treatment. The knowledge and unique technology of the St. Radboud is housed at Soteria.

“Soteria Medical is excited to be working with ZIF and IIG, who will help us proceed with the clinical testing of our Remote Controlled Manipulator (RCM) at St. Radboud, and to finalize the product design for the planned market launch later in 2014,” says CEO Jan Sabisch.


More information about Soteria Medical.

    ARCHIVES

    March 2020
    April 2018
    November 2017
    September 2017
    May 2017
    January 2017
    September 2016
    March 2016
    February 2016
    December 2015
    November 2015
    September 2015
    July 2015
    June 2015
    February 2014
    January 2014
    January 2013

    CATEGORIES

    All
    DOVIDEQ Medical
    Eaglet Eye
    Illuxtron
    Inno4Life
    MAGnetIC
    MIMETAS
    Soteria Medical BV
    Toxys

ZEEUWS INVESTMENT FUND
Edisonweg 41a | 4382 NV | Vlissingen | The Netherlands | + 31 (0)6 24810367 | johan@zeeuwsinvesteringsfonds.nl | Privacy policy